A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation

MLA

Shiri Curelaru, et al. “A Favorable Outcome in an Infantile-Onset Pompe Patient with Cross Reactive Immunological Material (CRIM) Negative Disease with High Dose Enzyme Replacement Therapy and Adjusted Immunomodulation.” Molecular Genetics and Metabolism Reports, vol. 32, no. 100893-, Sept. 2022. EBSCOhost, https://doi.org/10.1016/j.ymgmr.2022.100893.

APA

Shiri Curelaru, Ankit K. Desai, Daniel Fink, Yoav Zehavi, Priya S. Kishnani, & Ronen Spiegel. (2022). A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation. Molecular Genetics and Metabolism Reports, 32(100893-). https://doi.org/10.1016/j.ymgmr.2022.100893

Chicago

Shiri Curelaru, Ankit K. Desai, Daniel Fink, Yoav Zehavi, Priya S. Kishnani, and Ronen Spiegel. 2022. “A Favorable Outcome in an Infantile-Onset Pompe Patient with Cross Reactive Immunological Material (CRIM) Negative Disease with High Dose Enzyme Replacement Therapy and Adjusted Immunomodulation.” Molecular Genetics and Metabolism Reports 32 (100893-). doi:10.1016/j.ymgmr.2022.100893.